Amelia Langston, MD
Medical Oncology · Atlanta, GANPI 1346357019
Payments from drug & device makers
Across 295 payments — averaging $6976.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$965K
- Incyte Corporation$335K
- Takeda Pharmaceuticals U.S.A., Inc.$280K
- AbbVie$232K
- CSL Behring$105K
- National Marrow Donor Program$81K
- plus $59K from 9 others
Across 8 payments — averaging $2747.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$22K
- Gilead$109
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 18 | $964,653 |
| Incyte Corporation | 149 | $334,900 |
| Takeda Pharmaceuticals U.S.A., Inc. | 41 | $280,350 |
| AbbVie | 13 | $232,099 |
| CSL Behring | 17 | $105,461 |
| National Marrow Donor Program | 20 | $80,981 |
| Deciphera Pharmaceuticals Inc. | 3 | $29,480 |
| Genentech, Inc. | 1 | $11,935 |
| Sanofi US Services Inc. | 11 | $10,566 |
| Kadmon Corporation LLC | 3 | $3,011 |
| Modernatx, Inc. | 5 | $2,475 |
| Genentech USA, Inc. | 4 | $1,380 |
| Novartis | 6 | $360 |
| Astellas Pharma US Inc | 2 | $191 |
| Gilead | 2 | $94 |
How this compares
$2,057,935 in reported general payments places this provider in the 85th percentile of 68 medical oncology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Atlanta
- Suresh RamalingamAtlanta$10.5M
- Jonathan KaufmanAtlanta$7.7M
- Nabil SabaAtlanta$2.8M
- Olumide GbolahanAtlanta$2.7M
- Bradley CarthonAtlanta$2.7M
- Ragini KudchadkarAtlanta$2M
- Nisha JosephAtlanta$1.7M
- Patricia RichAtlanta$1.1M
- Eyal MeiriAtlanta$1.1M
- Dong ShinAtlanta$406K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.